CHIP involves in non-small cell lung cancer prognosis through VEGF pathway

CORC > 上海应用物理研究所 > 中国科学院上海应用物理研究所 > 中科院上海应用物理研究所2011-2017年

	CHIP involves in non-small cell lung cancer prognosis through VEGF pathway
	Qian, TT; Wang, J; Wang, QF; Liu, YC; Yu, SJ; Wang, ZQ; Sun, DM; Wang, SL
刊名	BIOMEDICINE & PHARMACOTHERAPY
	2016
卷号	83 页码:271-276
关键词	NSCLC CHIP VEGF-VEGFR2 Prognosis
ISSN号	0753-3322
通讯作者	Qian, TT (reprint author), Tongji Univ, Sch Life Sci & Technol, 1239 Siping Rd, Shanghai 200092, Peoples R China.
英文摘要	Aim: CHIP (c-terminal Hsp70-interacting protein) is an E3 ligase playing vital roles in various cancers. The VEGF pathway has become an important therapeutic target in non-small cell lung cancer (NSCLC). However, little is known about the role of CHIP and the relationship between CHIP and VEGF-VEGFR2 (VEGF receptor 2) pathway in NSCLC. In this study we aimed to investigate the clinical function of CHIP in NSCLC and explore the relevant regulatory mechanism. Methods: QRT-PCR was performed to detect CHIP expression in NSCLC tissues. The association of CHIP expression and clinical parameters was analyzed using the Chi-square test. Kaplan-Meier and Cox analyses were performed to identify the role of CHIP in the prognosis of NSCLC patients. ELISA test was used to detect the VEGF secretion of NSCLC cells and western blot were used to detected the protein expression of VEGFR2 in NSCLC cells. Results: and the results revealed that CHIP expression was decreased in NSCLC tissues and significantly correlated with clinical stages, lymph node metastasis and distant metastasis (P < 0.05). Moreover, Kaplan-Meier and Cox regression analyses showed that patients with negative expression of CHIP had a shorter survival time and CHIP could be an independent prognostic biomarker. In addition, ELISA tests showed that CHIP negatively regulated the secretion level of VEGF. Furthermore, western blot assay indicated that the VEGFR2 protein level was reduced after CHIP over-expression. Conclusions: Taken together, our findings demonstrate for the first time that CHIP may serve as a promising prognostic biomarker for NSCLC patients and it may be involved in NSCLC angiogenesis through regulating VEGF secretion and expression of VEGFR2. (C) 2016 Published by Elsevier Masson SAS.
收录类别	SCI
语种	英语
WOS记录号	WOS:000390433400034
内容类型	期刊论文
源URL	[http://ir.sinap.ac.cn/handle/331007/26448]
专题	上海应用物理研究所_中科院上海应用物理研究所2011-2017年
推荐引用方式 GB/T 7714	Qian, TT,Wang, J,Wang, QF,et al. CHIP involves in non-small cell lung cancer prognosis through VEGF pathway[J]. BIOMEDICINE & PHARMACOTHERAPY,2016,83:271-276.
APA	Qian, TT.,Wang, J.,Wang, QF.,Liu, YC.,Yu, SJ.,...&Wang, SL.(2016).CHIP involves in non-small cell lung cancer prognosis through VEGF pathway.BIOMEDICINE & PHARMACOTHERAPY,83,271-276.
MLA	Qian, TT,et al."CHIP involves in non-small cell lung cancer prognosis through VEGF pathway".BIOMEDICINE & PHARMACOTHERAPY 83(2016):271-276.